Advertisement

Therapeutic Kinase Inhibitors

  • Ingo K. Mellinghoff
  • Charles L. Sawyers

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 355)

Table of contents

  1. Front Matter
    Pages i-x
  2. William Y. Kim, Norman E. Sharpless
    Pages 19-38
  3. Cristina Antonescu
    Pages 41-57
  4. Yixuan Gong, William Pao
    Pages 59-81
  5. Christine A. Pratilas, Feng Xing, David B. Solit
    Pages 83-98
  6. Adil Daud, Boris C. Bastian
    Pages 99-117
  7. Ross L. Levine
    Pages 119-133
  8. Ingo K. Mellinghoff, Nikolaus Schultz, Paul S. Mischel, Timothy F. Cloughesy
    Pages 135-169
  9. Rakesh Kumar, Rafael G. Amado
    Pages 173-188
  10. Timothy A. Chan, Stephen B. Baylin
    Pages 189-216
  11. Back Matter
    Pages 233-234

About this book

Introduction

Cancer drug development is currently undergoing a profound shift. Drugs targeting fundamental cellular processes such DNA-replication and microtubule function, often referred to as “chemotherapy” and still the backbone of most cancer treatment regimens, are increasingly being complemented by or replaced with kinase inhibitors. This new class of drugs targets enzymes which provide growth and survival signals to cancer cells by transferring phosphate groups from Adenosine-5'-triphosphate (ATP) to other proteins, lipids, nucleotides, and carbohydrates. 

This book summarizes the current state of kinase inhibitor therapy for cancer. Successful drug development relies on the expertise and dedication of many experts. To reflect this team approach to finding new kinase inhibitors and defining their optimal use for cancer treatment, the editors invited experts in academia and pharmaceutical industry to share their insights into various aspects of this process, ranging from the first chemical screens, to preclinical testing and disease-focused clinical drug development. The editors hope these lessons will be instructive for the novice as well as the expert.

Keywords

Mitogen Activated Protein Kinase (MAPK) Raf kinases biomarkers chemical library clinical trial design drug development drug efficacy epigenetics gastrointestinal stromal tumor (GIST) genetically engineered mouse models (GEMMs) glioblastoma lung adenocarcinoma lung cancer melanoma myeloproliferative neoplasms small molecules

Editors and affiliations

  • Ingo K. Mellinghoff
    • 1
  • Charles L. Sawyers
    • 2
  1. 1., Human Oncology & Pathogenesis ProgramMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2., Human Oncology & Pathogenesis ProgramMemorial Sloan-Kettering Cancer CenterNew YorkUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-28296-6
  • Copyright Information Springer-Verlag Berlin Heidelberg 2012
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Biomedical and Life Sciences
  • Print ISBN 978-3-642-28295-9
  • Online ISBN 978-3-642-28296-6
  • Series Print ISSN 0070-217X
  • Buy this book on publisher's site
Industry Sectors
Pharma
Biotechnology
Consumer Packaged Goods